CEST-EPI has been shown to be effective an a non-invasive biomarker to distinguish between IDH1 mutant and wild type gliomas, and also 1p/19q codeleted from intact IDH1 mutant gliomas25,26. This evidence concerns the gene IDH1 and central nervous system cancer.